Monoclonal Antibody Treatment for COVID-19

What is regeneron?

Regeneron is the name of a publicly traded pharmaceutical company whose COVID antibody cocktail, REGN-COV2, has shown to reduce viral load and the time to alleviate symptoms in non-hospitalized patients with COVID-19.

What is REGN-COV2 made of?

REGN-COV2 is a cocktail of two monoclonal antibodies, casirivimab and imdevimab, that is administered through IV infusion. Casirivimab and imdevimab are monoclonal antibodies that are specifically directed against the spike protein of COVID-19 (SARS-CoV-2).

What are monoclonal antibodies?

Monoclonal antibodies are laboratory-made proteins that mimic the immune system’s ability to fight off harmful pathogens such as viruses. In the case of casirivimab and imdevimab, they are monoclonal antibodies that target the spike protein of SARS-CoV-2 and block the virus’ attachment and entry into human cells.

IS regeneron fda-approved?

As of November 2020, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for casirivimab and imdevimab to be administered together for the treatment of mild to moderate COVID-19 in adults and pediatric patients (12 years of age or older weighing at least 40 kilograms) who have tested positive for SARS-CoV-2 viral testing and who are at high risk for progressing to severe COVID-19. This includes those who are 65 years of age or older or who have certain chronic medical conditions.

IS regeneron covered by insurance?

Insurance for Regeneron treatment varies by insurance provider. Pulse & Remedy provides all necessary forms for you to submit insurance claims to your insurance company for reimbursement.